BAG5 Knockout T-47D Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the T-47D human breast ductal carcinoma cell line, designed for loss-of-function studies of the BAG5 gene. This product provides a genetically heterogeneous pool of cells with targeted disruption at the BAG5 locus, enabling investigation of BAG5-deficiency in a hormone-responsive breast cancer model.
The T-47D cell line is an estrogen receptor (ER)-positive and progesterone receptor (PR)-positive human breast ductal carcinoma originally isolated from a pleural effusion. It serves as a well-characterized model of hormone-responsive breast cancer, widely used to study estrogen signaling, endocrine therapy resistance, and the luminal A subtype. T-47D cells retain epithelial morphology and functional hormone receptors, making them relevant for translational research in cancer biology and protein homeostasis.
BAG5 encodes a co-chaperone that acts as a nucleotide exchange factor for Hsp70 (HSPA1A/HSPA8), inhibiting its ATPase activity to regulate protein folding and degradation. Its expression is controlled by HSF1 under heat shock or oxidative stress. BAG5 interacts with Hsp70, Parkin (PARK2), CHIP (STUB1), and HSPBP1, modulating protein quality control, Parkin-mediated mitophagy, and autophagy flux. Knockout of BAG5 may disinhibit Hsp70, altering the balance between pro-survival and apoptotic pathways.
In the hormone-responsive T-47D breast cancer model, BAG5 knockout provides a system to study Hsp70-mediated protein homeostasis under steroid signaling and ER stress. The polyclonal population captures tumor heterogeneity, enabling analysis of BAG5-dependent mitophagy and apoptosis across diverse cells. This model is valuable for investigating how BAG5 loss sensitizes cells to proteotoxic stress and endocrine therapies, offering insights into drug resistance.
This product supports functional studies of BAG5 in breast cancer, Hsp70 pathway investigations, drug screening, and chemotherapy resistance research. Key assays include Western blotting for BAG5, Hsp70, and cleaved caspase-3; RT-qPCR; Annexin V/PI apoptosis assays; LC3-I/II autophagy flux analysis; MTT proliferation assays; co-immunoprecipitation of BAG5-Hsp70 complexes; and drug sensitivity testing with doxorubicin or tamoxifen. For further technical details, please contact Ascent Research.
